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Abstract 36 
Purpose  37 
To study the effect of modified frankfurters and pâtés: a) reduced-fat products (RF) 38 
(15.3% and 15.2% fat, respectively); b) n-3-enriched reduced-fat products (n-3 RF) 39 
(15.1% and 15.5% fat, respectively) and c) normal-fat products (NF) (18% and 30.8% 40 
fat, respectively) on lipids, lipoproteins, atherogenic ratios, oxidized LDL and blood 41 
pressure of volunteers at high CVD risk. 42 
Methods  43 
Twenty-two volunteers were enrolled in a sequential study of 3 consecutive 4-wk 44 
periods separated by 4-wk washout periods.  45 
Results  46 
LDL-cholesterol (p<0.01), oxidized LDL, LDL-cholesterol/HDL-cholesterol (both 47 
p<0.05) were significantly affected by the overall intervention. Compared to baseline, 48 
LDL-cholesterol decreased significantly (p=0.012) during the RF period; the LDL-49 
cholesterol/HDL-cholesterol ratio (p=0.08) and the diastolic blood pressure (p=0.06) 50 
also decreased, although non-significantly, after RF consumption. LDL-cholesterol 51 
(p=0.040) and oxidized LDL (p=0.016) increased significantly after NF product 52 
consumption; systolic blood pressure did not show significant variations after this 53 
period. No significant differences, in absolute or relative changes, were observed 54 
between RF and n-3 RF consumption for any parameter tested. However, LDL-55 
cholesterol, oxidized LDL and the LDL-cholesterol/HDL-cholesterol ratio were lower 56 
(12%, 15% and 10%, respectively) after n-3 RF vs NF product consumption. Oxidized 57 
LDL was approximately 15% lower after RF vs NF product consumption. 58 
Conclusions  59 
The regular consumption of RF meat products, enriched in n-3 fatty acids or not, 60 
positively affects the lipoprotein profile of volunteers, decreasing LDL-cholesterol and 61 
oxidized LDL levels and, thus, future risk of cardiovascular accident. On comparison 62 
with the effects of NF product intake, the responses to n-3 RF and RF products differ, 63 
and while n-3 RF intake induces a reduction of LDL-cholesterol, oxidized LDL-64 
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cholesterol and LDL-cholesterol/HDL cholesterol ratio, the intake of RF products 65 
modifies only the oxidized LDL level. 66 
Keywords: reduced fat, omega-3-enriched meat, cholesterol, lipids, lipoprotein, atherogenic 67 
ratio, blood pressure, Frankfurters, pâtés. 68 
Abbreviations: RF, reduced-fat meat; n-3 RF, reduced-fat meat enriched in n-3 fatty acids; LDL, 69 
low-density lipoproteins; HDL, high-density lipoproteins; NCD, non-communicable diseases; 70 
CHD, coronary heart disease; CVD, cardiovascular disease; PUFA, polyunsaturated fatty acids; 71 
MUFA, monounsaturated fatty acids, SFA, saturated fatty acids; EPA, eicopentaenoic acid; 72 
DHA, docosahexaenoic acid; EFSA, European Food Safety Authority; ALA, α-linolenic acid 73 
 74 
INTRODUCTION 75 
 Both diet and nutrition play important roles in the development of non-76 
communicable diseases (NCD), responsible for almost two thirds of the mortality 77 
worldwide. Thus, cardiovascular diseases (CVD) were responsible for the largest 78 
proportion of NCD deaths in individuals under the age of 70 years (39%), followed by 79 
cancers (27%) [1]. Unbalanced diet, as well as physical inactivity, smoking habits and 80 
harmful use of alcohol, are strongly associated with the development of several NCDs, 81 
including CVD [2].   82 
Epidemiological studies have provided evidence that saturated fat and trans-fat 83 
increase the risk of coronary heart disease (CHD) [3-5] and are frequently associated 84 
with meat and processed food consumption [6-7]. Saturated fat replacement by 85 
polyunsaturated fats or monounsaturated fats seems to reduce the risk, with stronger 86 
evidence for the polyunsaturated fats [8-10]. Olive oil is the primary source of fat in the 87 
Mediterranean diet, which has gained increasing recognition and worldwide interest as a 88 
model for healthful habits [11]. Olive oil contains a large amount of antioxidants 89 
relative to its polyunsaturated fatty acid (PUFA) content, and its consumption decreases 90 
low-density lipoprotein- (LDL-) cholesterol when compared to saturated fatty acids 91 
(SFA), and may slow the development of coronary atherosclerosis [12]. Alpha-linolenic 92 
acid (ALA) is the principal fatty acid of linseed oil, a polyunsaturated n-3 essential fatty 93 
acid with beneficial effects on cholesterol levels, decreasing both total and LDL-94 
cholesterol without affecting high-density lipoprotein- (HDL-) cholesterol [13]. This 95 
fatty acid has also been considered an acceptable alternative to fish oils [9] as, once 96 
consumed, it can be converted (to a limited extent): 20% into eicosapentaenoic acid 97 
(EPA) and 0.05% into docosahexaenoic acid (DHA) [14]. These long-chain n-3 PUFA 98 
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provide cardioprotective benefits as they have been shown to exert potent 99 
antiarrhythmic effects, improve vascular endothelial function and help lower blood 100 
pressure, platelet sensitivity and serum triglyceride levels when consumed at doses of 2-101 
4 g/day [15]. Based on scientific evidence regarding dietary fat consumption, the 102 
European Food Safety Authority (EFSA) considers that SFA and trans fatty acid intake 103 
should be as low as possible and sets adequate intakes for linoleic acid (4% of the 104 
energy of the diet), ALA (0.5% of the energy of the diet) and for EPA+DHA (250 mg) 105 
[16]. 106 
 Meat and meat products are an important group of nutritionally dense foods in 107 
the diets of many consumers around the world. In 2011, the global meat production was 108 
estimated to be 294.7 million tonnes [17], indicating the importance of meat and meat 109 
products in the diet. Because of the amount and frequency of consumption, contribution 110 
to dietary intakes of different nutrients, diversity of presentations, possibility of 111 
modifying their composition using non-meat ingredients, high consumer acceptability, 112 
etc., meat and meat products are excellent foods for delivering bioactive compounds 113 
without changing dietary habits [18-19]. This has led researchers and the meat industry 114 
to modify traditional formulations to make them healthier. There are a number of 115 
different strategies to modulate the presence in meat and meat products of numerous 116 
compounds (endogenous and exogenous) with different potential effects on the 117 
organism. Reformulation of meat products is one of the strategies that has been studied 118 
in order to develop meat-based functional foods [20]. This strategy has been used to 119 
replace animal fat by a combination of vegetable (olive and linseed) and fish oils and 120 
development of two types of healthier meat products with clearly different 121 
characteristics: frankfurters and pâtés [21-22]. The resulting pâtés and frankfurters 122 
present a balanced lipid profile and can be claimed to be high omega-3 fatty acid 123 
products according to a Commission Regulation of the EU [23] and the EFSA [24]. The 124 
potential target population in which the consumption of these reformulated meat 125 
products could improve health status is the group at cardiovascular risk. Cholesterol, the 126 
lipoproteins involved in its transport and overweight are risk factors of CVD [2, 25-26]. 127 
These factors could be modulated with the consumption of reduced-fat n-3 PUFA and 128 
MUFA-enriched products. In addition, different lipoprotein ratios [26-27], size, density 129 
and oxidation [28-30] have been used to assess CVD risk. The heterogeneity and 130 
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complexity of the processes involved in the development of CVD makes it necessary to 131 
use specific biomarkers when assessing the origin and development of this disease.  132 
Taking into account previously established premises, the authors hypothesize 133 
that the consumption of modified frankfurters and pâtés improves the lipoprotein profile 134 
of volunteers. The aim of the study was to assess assess the effect and the potential 135 
functionality of these previously developed reduced-fat, n-3-enriched meat products 136 
(frankfurters and pâtés) by means of an intervention study in subjects at risk for CVD, 137 
evaluating markers and indicators related to CHD. 138 
 139 
METHODS AND MATERIALS 140 
Subjects 141 
Twenty-two volunteers were enrolled in a crossover study and 21 completed the 142 
study (trial profile in fig. 1). Participants were selected from 48 subjects who were 143 
interested and contacted through advertisements in different universities, research 144 
centers and several noticeboards. The selected subjects fulfilled the inclusion criteria: 145 
total cholesterol levels > 200 mg/dl, LDL cholesterol levels > 110 mg/dl, overweight 146 
(BMI > 25 and < 34.9 kg/m
2
) and willingness to consume 200 g of frankfurters and 250 147 
g of pâté per week. The exclusion criteria were: use of drugs or phytosterol-enriched 148 
beverages/foods to control cholesterol levels, hypertension or obesity, regular 149 
consumption of n-3 enriched food products, intolerance or food allergy to any of the 150 
components of the meat products.  151 
They were also instructed to maintain a mixed diet (no avoidance of any food 152 
groups) and to replace the helpings of meat and meat products of their habitual diet with 153 
helpings of the provided meat products. The characteristics of the subjects of the 154 
intervention study are shown in Table 1. 155 
The study was approved by the Ethical Committee for Clinical Investigation of 156 
Hospital Universitario Puerta de Hierro-Madajahonda (Acta nº 261, dated 20/ 12/ 2010) 157 
and the Bioethical Committee of the Spanish National Research Council. All subjects 158 
gave their written informed consent after receiving oral and written information about 159 
the study.   160 
Study Design  161 
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The study was a non-randomized, controlled, crossover design of 5 months’ 162 
duration. The non-randomization was due to limitations in the production of the meat 163 
products in the pilot plant. Subjects consumed 800 g of frankfurters and 1 kg of pâtés 164 
during each of the three 4-week study phases (200 g of frankfurters and 250 g of pâtés 165 
per week), followed by a four-week washout interval. Every period lasted long enough 166 
to produce significant changes in the lipid profile and the lipoprotein levels [31], as well 167 
as to return to the baseline lipid profile after the washout periods [32,20]. During the 168 
washout periods the subjects followed their habitual diets, making it possible to 169 
compare the effect of the “healthier” meat product consumption against their habitual 170 
diets, thus proving the effectiveness of the regular consumption of these kinds of 171 
products [33].   172 
The outline of the study (fig. 2) was as follows: first phase, volunteers consumed 173 
RF products in which the fat source was 100% animal fat; second phase, n-3 RF 174 
products were consumed; third phase, NF frankfurters and pâtés were consumed. 175 
Subjects completed 3-d dietary records at the beginning of each period in order 176 
to analyze their diets and to confirm the substitution of the meat products in their 177 
ordinary meals. Complete analyses of the dietary records will be reported in another 178 
paper. 179 
During the second intervention period, the volunteers consumed 450 g of n-3 RF 180 
frankfurters and pâtés, which provided 2 g of n-3 fatty acids per day, 1.5 g of which 181 
were ALA and approximately 0.4 g, EPA + DHA.  182 
During each visit, blood samples and dietary records were collected and subjects 183 
given a new batch of meat products, when necessary, and a diet record. Overnight 184 
fasting blood samples were collected at the start and end of each period from all 185 
participants. Serum was separated from blood by centrifugation at 2,500 g x 15 min and 186 
kept frozen at -80ºC until analysis.   187 
Serum cholesterol (total, HDL-cholesterol and LDL-cholesterol), oxidized LDL 188 
and triglycerides were measured as CHD biomarkers to assess the impact of the regular 189 
consumption of different NF, RF and n-3 RF frankfurters and pâtés. 190 
 191 
Meat products 192 
Frankfurters and pâtés were developed in the pilot plant of the Instituto de 193 
Ciencia y Tecnología de Alimentos y Nutrición (ICTAN, CSIC). Three different 194 
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batches were produced, a) reduced-fat products (RF) (15% fat), b) reduced-fat (15% fat) 195 
n-3-enriched meat products (n-3 RF) in which the animal fat source (pork backfat) was 196 
replaced by a combination of olive, linseed and fish oil [21-22], and c) normal-fat 197 
control products (NF) (18% fat for frankfurters, 30% fat for pâtés). This oil combination 198 
was used as an ingredient in the form of an oil-in-water emulsion, composed of olive, 199 
linseed and fish oil (44.39%, 37.87% and 17.74%, respectively).  200 
RF frankfurters and pâtés were reformulated by reducing their fat content, and n-201 
3 RF products by reducing their fat content and replacing the pork backfat with the oil 202 
combination mentioned above, yielding meat products with an improved lipid profile 203 
[21-22]. The NF products were similar (in fat content) to those usually found in the 204 
market. Additionally, the technological, sensorial and microbiological viability of these 205 
products has been established [21-22,34]. In this study, some slight composition 206 
modifications have been introduced in the frankfurter development in order to achieve 207 
the established fat levels. The nutrient profiles of the different pâtés and frankfurters of 208 
the study are shown in Table 2.  209 
Containers of 250 g of pâté and 200 g of vacuum-packed frankfurters were 210 
prepared. At the beginning of every intervention period, the meat products were 211 
delivered and volunteers were instructed to store them under refrigeration until 212 
consumption. Frankfurters and pâtés were ready for consumption. Once open, the 213 
containers had to be consumed within a 1-week period. 214 
 215 
Analytical Methods 216 
All the blood samples from each volunteer were analyzed on the same day in order to 217 
minimize the analytical variability associated with different days. 218 
LDL- and HDL- cholesterol were assessed with an enzymatic colorimetric 219 
procedure (BioSystems LDL and HDL Direct). Total cholesterol and triglyceride 220 
concentrations were also assessed by enzymatic colorimetric kit (BioSystems 221 
Cholesterol and BioSystems Triglycerides Glycerol phosphate oxidase/peroxidase, 222 
respectively). Serum oxidized LDL level was quantified by an ELISA system 223 
(Mercodia AB, Uppsala, Sweden). 224 
The interassay and intraassay coefficients of variation (CV) for total, LDL-225 
cholesterol, HDL-cholesterol and triglycerides were 1.9%, 2.0%, 1.3% and 2.6%, and 226 
1.1%, 0.7%, 0.8% and 1.7%, respectively.  227 
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Different indexes were also calculated as CHD-biomarkers: the Atherogenicity 228 
Index (total cholesterol/HDL-cholesterol) as proposed by Castelli [26], the LDL-229 
cholesterol/HDL-cholesterol ratio, and the atherogenicity of LDL, calculated by the 230 
molar ratio of triglycerides to HDL cholesterol. 231 
 232 
Statistical Analysis 233 
Sample size calculation was performed on the basis of a mean value for baseline 234 
LDL-cholesterol of 140 mg/dl. A sample size of 22 subjects (SD=16) is necessary to 235 
obtain a 10% difference in LDL-cholesterol (14 mg/dl) with 80% power and an alpha 236 
error of 0.05. Results are expressed as mean ± SD. All data had normal distribution, 237 
assessed using a normal probability plot and the Kolmogorov-Smirnov test.  There were 238 
no statistical differences (p>0.05) between the mean baseline levels in any the three 239 
phases of the study (general linear model, GLM, repeated measures); therefore, the 240 
baseline value for each parameter was the mean of the three samples from each 241 
volunteer collected at the beginning of each period in the intervention study. Student´s t 242 
test for paired data was used to assess the significance of changes in each period 243 
compared to baseline. In addition, a GLM (repeated measures) followed by the 244 
Bonferroni test was employed to assess the statistical differences between periods for 245 
each parameter in terms of relative percent changes. Differences were also tested after 246 
adjusting data for alcohol and olive oil consumption. Chi square test was used to assess 247 
changes in prevalences of individuals with altered lipid, lipoprotein and blood pressure 248 
levels. All the statistical analyses were performed using IBM SPSS Statistics 19.0 (IBM 249 
Corporation, Somers, NY, USA). 250 
 251 
RESULTS 252 
 Baseline levels at the initiation of the first intervention period of the study are 253 
shown in Table 1. The subjects had high total and LDL-cholesterol levels and an 254 
average BMI of 28.8 kg/m
2
. The volunteers showed no hypertension or high fasting 255 
blood glucose levels.  256 
 Table 2 shows some nutritional information on the frankfurters and pâtés used in 257 
the intervention study. RF and NF products differ mainly in the fat quantity, with the 258 
energy content in the RF products reduced by nearly 30%. n-3 RF products showed a 259 
different lipid profile, providing higher PUFA and lower SFA percentages. According 260 
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to our dietary records, frankfurters and pâtés prepared for the study were adequately 261 
introduced into the habitual diets of the subjects (unpublished data).  262 
 Table 3  shows the intake effect of the frankfurters and pâtés (RF, n-3 RF and 263 
NF) on lipids, lipoprotein, CVD risk factors and blood pressure. There were statistically 264 
significant differences in LDL-cholesterol levels (p<0.01), oxidized LDL (p<0.01) and 265 
the LDL-cholesterol/HDL-cholesterol ratio (p<0.05). On comparing blood lipid 266 
concentrations after the diet with n-3 RF products with baseline, there were decreases in 267 
the LDL-cholesterol level (7 mg/dl) and in the LDL-cholesterol/HDL-cholesterol ratio 268 
(0.14, p<0.1) that were of borderline statistical significance, with no variation of the 269 
oxidized LDL; by contrast, blood lipids underwent no variation after the first period, 270 
during which the RF products were consumed. 271 
When the NF frankfurters and pâtés (similar to commercial products) were 272 
consumed, LDL-cholesterol and oxidized LDL levels increased (8.4 mg/dl and 7.5 U/l, 273 
respectively. However, no significant changes were found in blood pressure; the results 274 
showed small variations when comparing each period with the baseline. Systolic blood 275 
pressure was increased (3.1 mmHg, p<0.1) in the third period (after NF product intake), 276 
while diastolic blood pressure decreased (2.4 mmHg, p<0.1) in the second period (after 277 
consumption of n-3 RF products). 278 
 When comparing relative percent changes among periods, no statistical 279 
differences were found between the first and the second periods (n-3 RF vs RF) in any 280 
of the parameters measured (Fig 3a); however, significant differences were observed 281 
between the second and third phases (n-3 RF vs NF) (Fig 3b) and between the first and 282 
third phases (RF vs NF) (Fig 3c). Comparing the n-3 RF frankfurters and pâtés 283 
consumption period with the NF consumption period, significant (p<0.01) reductions 284 
were observed in LDL-cholesterol (11.8%), oxidized LDL (17.3%) and the LDL-285 
cholesterol/HDL-cholesterol ratio (10.8%, p<0.05) (Fig 3b). Comparing the RF product 286 
consumption phase with the NF phase, there was a significant reduction (14.5%) in the 287 
oxidized LDL level (Fig 3c). 288 
 289 
DISCUSSION 290 
 Most studies of diet and CVD have focused on dietary lipids. Until very 291 
recently, public health recommendations have been concentrated on limiting the intake 292 
of total dietary fat. Based on the most recent evidence, the recommendations for CVD 293 
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risk reduction are now focused, among other major points, on the reduction of saturated 294 
fat intake [16,35]. However, meat products are a great source of SFA and limiting their 295 
fat content does produce important changes in blood lipids [36-38]. In the present study, 296 
we addressed the question of whether the consumption of RF n-3-enriched frankfurters 297 
and pâtés could produce changes in blood lipids and different markers of CVD. We also 298 
wanted to assess the benefits of the consumption of these n-3-enriched products versus 299 
RF meat products, and draw a comparison with the consumption of non-modified 300 
frankfurters and pâtés (with compositions similar to commercial ones), in terms of CVD 301 
risk markers. RF frankfurters and pâtés were produced by decreasing the quantity of fat 302 
(pork backfat as main fat source) used in the manufacture of the meat products. As 303 
mentioned above, for n-3 RF frankfurters and pâtés, an oil-in-water emulsion was 304 
prepared as fat source. These oils were selected, among other reasons, to produce 305 
frankfurters and pâtés with a fatty acid composition in line with health 306 
recommendations; we wanted to reduce the SFA levels of these products by increasing 307 
their total PUFA and n-3 PUFA contents, with slight modifications in their 308 
monounsaturated fatty acid (MUFA) content (as recommended by the EFSA [16]), but 309 
we also wanted to obtain stabilized products and with sensory acceptance among 310 
consumers. Olive oil is very rich in MUFA and has a high biological value, attributed to 311 
a high ratio of vitamin E to PUFA. It has a lower ratio of SFA/MUFA than any other 312 
vegetable oil and contains antioxidant substances in optimum concentrations [39]; 313 
therefore, it was the main oil (44.39%) of the emulsion. To increase the PUFA content 314 
we selected linseed oil (37.87%) (with low levels of SFA [13]), which provides a great 315 
amount of the n-3 PUFA, ALA, and we also used fish oil (17.74%) for its content in the 316 
long-chain n-3 PUFA, EPA and DHA, to achieve an adequate intake of n-3 fatty acids. 317 
Nutritional recommendations for n-3 fatty acids are estimated to be between 1.4 - 3 318 
g/day [24,40-41], while the recommendations for long-chain n-3 PUFA range between 319 
180-1000 mg/day [24,16,40]. The n-3 RF products were consumed during the second 320 
phase of the study, providing 0.43 g of EPA+DHA per day, almost the 500 mg/day 321 
recommended by the International Society for the Study of Fatty Acids and Lipids 322 
(ISSFAL) [42], and fulfilling the adequate intake established by the EFSA (250 mg) 323 
[16]. Considering an average energy intake of 2000 kcal, ALA provided 0.78% of the 324 
energy through the consumption of the frankfurters and pâtés during the second phase 325 
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of the intervention study. The adequate ALA intake established by the EFSA is 0.5% of 326 
the energy of the diet [16].  327 
 In the present study, the consumption of the reformulated frankfurters and pâtés 328 
(RF and n-3 RF) over four weeks did not induce any significant effect on bodyweight. 329 
Although the meat products tested differ in their energy content (about 145 kcal 330 
between reduced fat-products and normal-fat products), this difference does not seem to 331 
affect bodyweight. Our group did not find bodyweight changes in previous studies in 332 
which 8 En% oleic acid was replaced by palmitic acid [43] or when walnut–restructured 333 
meat was consumed instead of restructured meat with a very low fat content [20]. The 334 
reformulated frankfurters and pâtés (RF and n-3 RF) induced a reduction of 5.4% in the 335 
LDL-cholesterol level, with no other significant changes in total or HDL-cholesterol. 336 
Differences in fatty acids (decrease in SFA of 1.34 g/day and in linoleic acid of 0.34 337 
g/day, while linoleic and total PUFA omega-3 increased by 1.54 g and 1.93 g, 338 
respectively) were probably not enough to modify HDL-cholesterol, explaining, at least 339 
in part, the results obtained. 340 
The effect of oral contraceptives, alcohol and olive oil consumption on the 341 
results should be discarded as the data did not change significantly after adjustment for 342 
these variables. Due to the mixture of oils used in the reformulated frankfurters and 343 
pâtés, it is not easy to attribute the results to any of the vegetable and marine oils 344 
included in the RF. Similar results were observed after the consumption over four 345 
weeks of n-3 and oleic acid-enriched milk, with levels of oleic acid and EPA+DHA 346 
similar to those of reformulated meat products; there were no significant changes in 347 
total and HDL-cholesterol, and a reduction of LDL-cholesterol (9.4%) was observed 348 
Although ALA could also affect blood lipid concentration, a systematic review of 14 349 
studies (with a minimum of four weeks’ duration) concluded that ALA consumption did 350 
not significantly modify blood lipids [45]. In addition, a recent meta-analysis evaluating 351 
the effects of EPA and DHA on blood lipids found that DHA significantly raised LDL-352 
cholesterol (7.23 mg/dl) and HDL-cholesterol (4.49 mg/dl), whereas EPA non-353 
significantly reduced LDL-cholesterol and increased HDL-cholesterol levels [46]. 354 
Another meta-analysis concluded that fish oil consumption produced no significant 355 
changes in total cholesterol, but did produce a small increase in HDL- and LDL-356 
cholesterol (1.6 mg/dl and 6 mg/dl, respectively) [47].  357 
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Although there is not enough evidence to support the role of n-3 fatty acid 358 
consumption in the changes produced in lipoproteins, studies indicate that the use of 359 
fish oil is associated with CHD risk reduction. One of the mechanisms responsible for 360 
this is the reduction of triglyceride levels, accomplished by decreasing the production of 361 
hepatic triglycerides and increasing the clearance of plasma triglycerides [48]. In the 362 
present study, no significant modification of serum triglyceride levels was observed 363 
after the consumption of n-3 RF products. This circumstance could be related to the low 364 
baseline levels of serum triglycerides (125 mg/dl) and also to the wide variability of this 365 
parameter among volunteers. Other constituents of the reformulated frankfurters and 366 
pâtés might also have a role in this finding. Moreover, normally a change of 2 En% in 367 
the form of EPA+DHA is necessary to decrease triglycerides [49]. There were no 368 
significant changes in triglyceride levels after the consumption of RF or NF frankfurters 369 
and pâtés when compared with the other periods of the study.  370 
In the third period of the study, after the NF product consumption, LDL-371 
cholesterol and oxidized LDL levels increased by 6.4% and 7.5%, respectively. 372 
Accordingly, consumption of NF frankfurters and pâtés similar to commercial ones 373 
produced an increase in the risk of CVD by increasing LDL-cholesterol and oxidized 374 
LDL levels, while a consumption of RF frankfurters and pâtés avoided this effect. The 375 
latter effect may be attributable first to the amounts of fat and SFA in the meat products 376 
consumed (more fat, SFA and oleic acid (5.3 g/day, 3.26 g/day and 3.5 g/day, 377 
respectively), but 1.9 g/day less of omega-3). 378 
A better approximation to the effects of the three different frankfurters and pâtés 379 
can be achieved by comparing their relative changes (Fig 1) n-3 RF product intake 380 
decreased total, LDL- and HDL-cholesterol when compared with NF products (0.5%, 381 
11.8%, 2.1%, respectively), although significant effects were found only in LDL-382 
cholesterol. Similarly, after 4 weeks of dietary intervention, a 7.8% reduction of LDL-383 
cholesterol was observed after replacing 40% of the fat in the background diet with 384 
virgin olive oil [50]. The consumption over four weeks of rapeseed oil (rich in ALA) 385 
produced a significant reduction in total and LDL-cholesterol when compared with a 386 
diet rich in SFA [51]. The bulk of the evidence shows that substitution of SFA by either 387 
MUFA or PUFA leads to reductions in total and LDL-cholesterol [52]. But there is 388 
considerable evidence to show that a PUFA diet increases the oxidative susceptibility of 389 
LDL, compared to a MUFA-enriched diet, due to the greater degree of unsaturation 390 
13 
 
present in PUFA [9]. Our group found that a substitution of MUFA by SFA (approx 8% 391 
E) significantly increased LDL-cholesterol but decreased serum and LDL oxidation 392 
[43]. Oxidized LDL has been found to correlate with the extent of CHD and to be an 393 
independent predictor of an atherosclerotic plaque occurrence; thus, elevated levels of 394 
oxidized LDL might be used as an early indicator of CVD [53]. In the present study, n-3 395 
RF and RF decreased 17.3% and 14.5%, respectively, in comparison with NF products; 396 
the oxidizability of LDL suggests that a regular consumption of both RF products could 397 
be effective in reducing the atherogenicity of LDL. Olive oil contains hydroxytyrosol 398 
and other potent antioxidants [54] that have been proven to decrease oxidation in LDL 399 
[55]. A reduction of oxidized LDL of 16% was found after a six-week consumption of 400 
turnip rapeseed oil (rich in MUFA and PUFA) in men with metabolic syndrome [53]. 401 
Although total, HDL- and LDL-cholesterol levels were non-significantly lowered by 402 
consuming RF products (in comparison with NF products), there was a decrease 403 
(p<0.05) in the oxidized LDL levels.  404 
Thus, a “good” mixture of fatty acids or a reduction of animal fat could lead to 405 
protection against the oxidation of the LDL molecules. The changes in the oxidized 406 
LDL/LDL-cholesterol ratio were non-significant (Table 3), but after the consumption of 407 
NF products, the ratio tended to increase slightly (from 0.42 to 0.45).  408 
Surprisingly, no significant differences were found when comparing the 409 
consumption of RF and n-3 RF frankfurters and pâtés (in terms of relative changes; see 410 
Figure 1). But downward trends were observed in LDL cholesterol (4.7%) and oxidized 411 
LDL (2.8%). In addition, the comparison of RF versus NF product consumption led to 412 
non-significant reductions in total, HDL- and LDL-cholesterol (1.6%, 7.1%, 2.2%, 413 
respectively). These results are in agreement with those reported in other studies 414 
[38,56]. 415 
Epidemiological and clinical studies have clearly suggested that cholesterol 416 
levels do not provide incremental predictive value over cholesterol ratios in identifying 417 
people at risk for CHD [57]. Nowadays, different ratios of lipid fractions are being used 418 
as predictors or as indicators of CHD risk reduction. Total cholesterol/HDL-cholesterol, 419 
LDL-cholesterol/HDL-cholesterol and the molar triglyceride/HDL-cholesterol ratios are 420 
widely used. This study suggests that the consumption of n-3 RF frankfurters and pâtés 421 
in place of NF products can reduce CVD risk as they significantly reduced the LDL-422 
cholesterol/HDL-cholesterol ratio.  423 
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In the present study, the subjects lowered their high CVD risk by reducing their 424 
LDL-cholesterol level below 130 mg/dl (high risk factor for CVD [58]). Almost 67% of 425 
the subjects had LDL-cholesterol levels above 130 mg/dl, but after consumption of the 426 
n-3 RF products, the percentage decreased to 38% (p=0.064). 427 
Blood pressure is a major risk factor for CVD [59]. Slight, non-significant 428 
variations were observed after the consumption of the different meat products. In 429 
general, 3 En% in the form of EPA is needed to decrease blood pressure. Due to safety 430 
regulations, industrial meat products normally contain relatively high amounts of NaCl. 431 
All the meat products described here contained 2g NaCl/100 g (approximately 950 mg 432 
Na/100 g [60]), similar to commercial frankfurters and pâtés, but lower than other meat 433 
products like cured ham. The apparent refractoriness of normotensive individuals in 434 
terms of decreasing their blood pressure has been reported in several studies, as 435 
nutritional strategies have no effect in normotensive people or in hypertensives who are 436 
non-salt-sensitive responders [61-62]. Moderate NaCl restriction induced only 437 
negligible blood pressure reduction in normotensive individuals [61]. In our study, 438 
blood pressure levels generally remained below 140-90 mm Hg, cut-off point for 439 
defining hypertension [63].  440 
In summary, we can conclude that, in comparison to consumption of NF meat 441 
products, the regular intake of n-3-enriched RF frankfurters and pâtés does decrease the 442 
LDL-cholesterol and oxidized LDL levels, as well as the LDL-cholesterol/HDL-443 
cholesterol ratio. The consumption of any of the meat products in the study did not 444 
provoke any significant increase in the total cholesterol or blood pressure. The 445 
development and consumption of RF meat products, enriched or not in n-3 PUFA, 446 
appears to be a suitable strategy to decrease CVD risk in meat consumers, although the 447 
intake effects of n-3 RF and RF products differ, and while n-3 RF intake induces a 448 
reduction in LDL-cholesterol, oxidized LDL-cholesterol and LDL-cholesterol/HDL 449 
cholesterol ratio, the intake of RF products modifies only the oxidized LDL level.  450 
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Fig 3. Relative percent changes in total cholesterol (CT), LDL-cholesterol (LDL-c), 
HDL-cholesterol (HDL-c), oxidized LDL (LDL-ox) and the LDL-cholesterol/HDL-
cholesterol ratio when comparing the different periods of the study: a) Changes after 2
nd
  
phase of the study compared with results after  1
st
 phase, b) Changes after 2
nd
 phase of 
the study compared with results after 3
rd
 phase; c) Changes after 1
st
 phase of the study 
compared with results after 3
rd
 phase. *Significantly different (*p<0.05; **p<0.01; 
Bonferroni’s test) 
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Table 1. Baseline characteristics of the volunteers (n=22, 18 men and 4 women) at the start of 
the intervention study (Mean ± SD) 
 
Baseline levels 
Age (years) 43.9 ± 12.0 
Weight (kg) 82.69 ± 10.8 
Body mass index (kg/m
2
) 28.8 ± 2.8 
Total cholesterol (mg/dl) 233.3 ± 23.6 
HDL-cholesterol (mg/dl) 47.1 ± 9.0 
LDL-cholesterol (mg/dl) 134.2 ± 23.7 
Triglycerides (mg/dl) 125.3 ± 70.9 
Blood glucose (mg/dl) 91.3 ± 16.6 
Systolic blood pressure (mm Hg) 
Diastolic blood pressure (mm Hg) 
121.1 ± 10.7 
76.1 ± 10.2 
Smoking habit 
a 
15 non-smokers / 7 smokers 
Alcohol consumption 8 never / 12 sometimes / 2 regularly 
a 
Smokers: 10-20 cigarettes/day 
HDL, high-density lipoproteins; LDL, low-density lipoproteins; SD, standard deviation. 
 
2 
Table 2. Nutrient and lipid profile of the different frankfurters and pâtés consumed in the study  
 
 Reduced-fat products n-3-enriched reduced-fat products Normal-fat products 
 Frankfurter Pâté Frankfurter Pâté Frankfurter Pâté 
Protein (g/100g) 17.9 13.3 19.4 14.2 18.3 13.2 
Fat (g/100g) 
% of total fatty acids 
15.3 15.2 15.1 15.5 18.0 30.8 
SFA 
Palmitic acid 
Stearic acid 
39.4 
23.4 
13.8 
32.3 
20.5 
9.9 
19.3 
11.4 
5.4 
21.3 
13.6 
6.0 
39.4 
23.4 
13.8 
32.3 
20.5 
9.9 
MUFA 
Oleic acid  
49.5 
42.5 
58.3 
50.5 
46.9 
42.5 
42.5 
37.4 
49.5 
42.5 
58.3 
50.5 
PUFA 
Linoleic acid 
Linolenic acid 
EPA 
DHA 
Total omega-3 fatty acids (g/100g) 
10.6 
8.6 
0.6 
- 
- 
0.2 
9.0 
7.4 
0.5 
- 
- 
0.2 
33.6 
10.8 
17.7 
2.6 
1.7 
3.4 
35.6 
11.6 
17.5 
2.7 
1.8 
3.7 
10.6 
8.6 
0.6 
- 
- 
0.2 
9.0 
7.4 
0.5 
- 
- 
0.2 
Moisture (g/100g) 58.8 65.7 57.8 64.1 55.7 50.1 
Energy (kcal/100g) 212.6 203.4 216.9 211.8 238.8 345.5 
Data partially adapted from [21] and [22]. SFA: saturated fatty acids; MUFA: monounsaturated fatty acids; PUFA: polyunsaturated fatty acids; 
EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
3 
Table 3. Serum concentrations of lipids, HDL- and LDL-cholesterol and oxidized LDL, diverse atherogenic indexes, and blood pressure of 
volunteers in the different intervention periods  
 Baseline Final concentrations 
(Reduced-fat products) 
Final concentrations 
(n-3-enriched reduced-fat products) 
Final concentrations 
(normal-fat products) 
Statistical 
significance
1  
Bodyweight (kg) 
Diffrenece vs. baseline (CI95%); p 
82.6 ± 10.7 
 
82.5 ± 10.9 
-0.05 (-0.5, 0.4); p=0.800 
82.4 ± 10.7 
-0.15 (-0.6, 0.3); p=0.463 
83.0 ± 11.0 
0.4 (-0.15, 0.97); p=0.146 
p = 0.835 
Total cholesterol (mg/dl) 
Difference vs baseline (CI95%); p 
232.4 ± 20.7 
 
232.5 ± 20.4
a 
0.1 (-6.3, 6.5); p=0.978 
235.6 ± 30.3
a 
3.3 (-5.9, 12.4); p=0.463 
236.7 ± 26.5
a 
4.4 (-2.3, 11.0); p=0.188 
p = 0.656 
HDL-cholesterol (mg/dl) 
Difference vs baseline (CI95%); p 
47.7 ± 7.8 47.9 ± 9.7
a 
0.2 (-1.7, 2.0); p=0.870 
47.8 ± 8.9
a 
0.1 (-1.7, 1.9); p=0.924 
48.9 ± 10.9
a 
1.2 (-1.5, 3.9); p=0.360 
p = 0.633 
LDL-cholesterol (mg/dl) 
Difference vs baseline (CI95%), p 
137.2 ± 19.9 136.0 ± 24.6
ab 
-1.3 (-9.4, 6.8); p=0.747 
130.2 ± 24.5
a 
-7.0 (-12.3, -1.7); p=0.012 
145.7 ± 24.7
b 
8.4 (0.4, 16.4); p=0.040 
p = 0.007 
Triglycerides (mg/dl) 
Difference vs baseline (CI95%); p 
125.3 ± 62.7 117.6 ± 46.5
a 
-7.7 (-32.2, 16.8); p=0.518 
132.8 ± 74.2
a 
7.4 (-14.7, 29.5); p=0.491 
119.0 ± 46.2
a 
-6.4 (-19.3, 6.5); p=0.314 
p = 0.486 
Oxidized LDL (U/l) 
Difference vs baseline (CI95%); p 
57.8 ± 11.6 56.6 ± 10.3
a 
-1.2 (-4.8, 2.4); p=0.505 
55.8 ± 13.0
a 
-2.0 (-5.3, 1.3); p=0.219 
65.2 ± 16.3
b 
7.5 (1.5, 13.4); p=0.016 
p = 0.007 
Oxidized LDL/LDL-cholesterol 
Difference vs baseline (CI95%); p 
0.42 ± 0.08 0.42 ± 0.07
a 
0.00 (-0.03, 0.03); p=0.985 
0.43 ± 0.09
a 
0.01 (-0.03, 0.04); p=0.628 
0.45 ± 0.11
a 
0.03 (-0.01, 0.07); p=0.131 
p = 0.482 
Total cholesterol/HDL-cholesterol 
Difference vs baseline (CI95%); p  
5.00 ± 1.00 5.06 ± 1.14
a 
0.05 (-0.20, 0.30); p=0.678 
5.11 ± 1.19
a 
0.10 (-0.14, 0.34); p=0.399 
5.08 ± 1.29
a 
0.07 (-0.26, 0.40); p=0.660 
p = 0.972 
LDL-cholesterol/HDL-cholesterol 
Difference vs baseline (CI95%); p  
2.96 ± 0.64 2.97 ± 0.82
ab 
0.01 (-0.21, 0.23); p=0.943 
2.82 ± 0.70
a 
-0.14 (-0.31, 0.02); p=0.083 
3.14 ± 0.89
b 
0.18 (-0.08, 0.44); p=0.166 
p = 0.027 
Atherogenic index of LDL 
Difference vs baseline (CI95%); p 
1.23 ± 0.74 1.17 ± 0.66
a 
-0.06 (-0.31, 0.19); p=0.630 
1.32 ± 0.91
a 
0.09 (-0.16, 0.35); p=0.461 
1.17 ± 0.64
a 
-0.06 (-0.21, 0.09); p=0.410 
p = 0.521 
Systolic blood pressure (mm Hg) 
Difference vs baseline (CI95%); p 
121.2 ± 9.4 119.5 ± 10.2
a 
-1.7 (-5.0, 1.7); p=0.312 
119.5 ± 10.8
a 
-1.7 (-4.7, 1.4); p=0.265 
124.3 ± 14.1
a 
3.1 (-0.6, 6.8); p=0.098 
p = 0.223 
Diastolic blood pressure (mm Hg) 
Difference vs baseline (CI95%); p 
77.4 ± 9.3 75.4 ± 12.3
a 
-2.0 (-4.7, 0.7); p=0.146 
75.0 ± 8.6
a 
-2.4 (-5.0, 0.2); p=0.067 
76.4 ± 13.6
a 
-1.1 (-4.4, 2.3); p=0.517 
p = 0.471 
Different superscript letters within a given row indicate significantly different values (mean ± SD of 21 volunteers, with Bonferroni adjustment for multiple 
comparisons). HDL, high-density lipoproteins; LDL, low-density lipoproteins;  
1
General linear mode repeated measures; CI, confidence interval. 
 
